TY - CHAP M1 - Book, Section TI - Emergent Clinical Complications of Sickle Cell Disease A1 - Carden, Marcus A1 - Glassberg, Jeffrey A1 - Morris, Claudia R. A2 - Gladwin, Mark T. A2 - Kato, Gregory J. A2 - Novelli, Enrico M. PY - 2021 T2 - Sickle Cell Disease AB - Sickle cell disease (SCD) comprises a group of recessively inherited hemoglobinopathies that impact approximately 100,000 adults and children of various ethnicities and backgrounds in the United States and millions more worldwide.1,2 Although the clinical features of SCD vary from patient to patient, common clinical complaints in the emergency department (ED) result from a persistent hemolytic anemia and vasculopathy within the microcirculation, which leads to repeated episodes of vaso-occlusion and ischemia-reperfusion that can result in acute and chronic end-organ damage of every organ system.3,4 Patients with SCD have a shortened life expectancy compared to the general population due to these complications; however, most children with SCD in the United States can now expect to live to adulthood thanks to modern medical advances, including mandatory neonatal hemoglobinopathy screening, disease-specific immunization practices, early initiation of penicillin prophylaxis, hydroxyurea therapy, transfusion protocols, and parent education.5 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1179345373 ER -